After Trump Tax Break Pfizer Ends Funding For Alzheimer's, Parkinson's Research And Gives Billions to Investors
Nicole Goodkind,Newsweek
Jeff Borghoff was 51 years old when he began to experience memory loss and difficulty concentrating at work. The software developer could no longer gather his thoughts. He found himself putting co-workers on hold during conference calls to buy extra time to comprehend what they were saying. Eventually, he had to ask for a less stressful job.
The ******* of three began a year-long medical journey to search for an explanation until he got his diagnosis—early-onset Alzheimer’s, a degenerative disease with no cure.
Still, he had hope. Jeff's doctor told him that scientists were closing in on a cure, and advised him to look into clinical trials for new Alzheimer’s *******. “Clinical volunteers should consider themselves front line battle warriors in the cure for Alzheimer’s,” said Jeff. “Our participation is about saving multiple generations of lives.”
But in a bombshell decision that hampers hopes of a treatment or cure for the most expensive disease in America, Pfizer announced this week that it would end all research and development efforts into new ******* and treatments for Alzheimer’s and Parkinson’s disease.
The world’s third largest pharmaceutical company released a statement saying that as "a result of a recent comprehensive review” it would lay off nearly 300 scientists and end its “neuroscience discovery and early development efforts.”
"The report of Pfizer's decision to end it's Alzheimer's ******* research and trials is a gut punch to the millions of people with Alzheimer's, their caregivers and families let alone the folks that will be losing their jobs," said Jeff.
The fear is that this becomes a trend, said James Beck, the chief scientific officer at the Parkinson’s Foundation. “Other pharmaceutical companies are also weighing this option and if the biggest of the bunch decides to exit the party, it might have a ripple effect on the others,” he told Newsweek. Private foundations and government-funded research initiatives can work to keep up the pipeline of basic science, but ultimately it takes funding from a large company to get a treatment onto the shelves of CVS or Walgreens, he said.
https://www.yahoo.com/news/trump-tax-break-pfizer-ends-130002411.html
Nicole Goodkind,Newsweek
Jeff Borghoff was 51 years old when he began to experience memory loss and difficulty concentrating at work. The software developer could no longer gather his thoughts. He found himself putting co-workers on hold during conference calls to buy extra time to comprehend what they were saying. Eventually, he had to ask for a less stressful job.
The ******* of three began a year-long medical journey to search for an explanation until he got his diagnosis—early-onset Alzheimer’s, a degenerative disease with no cure.
Still, he had hope. Jeff's doctor told him that scientists were closing in on a cure, and advised him to look into clinical trials for new Alzheimer’s *******. “Clinical volunteers should consider themselves front line battle warriors in the cure for Alzheimer’s,” said Jeff. “Our participation is about saving multiple generations of lives.”
But in a bombshell decision that hampers hopes of a treatment or cure for the most expensive disease in America, Pfizer announced this week that it would end all research and development efforts into new ******* and treatments for Alzheimer’s and Parkinson’s disease.
The world’s third largest pharmaceutical company released a statement saying that as "a result of a recent comprehensive review” it would lay off nearly 300 scientists and end its “neuroscience discovery and early development efforts.”
"The report of Pfizer's decision to end it's Alzheimer's ******* research and trials is a gut punch to the millions of people with Alzheimer's, their caregivers and families let alone the folks that will be losing their jobs," said Jeff.
The fear is that this becomes a trend, said James Beck, the chief scientific officer at the Parkinson’s Foundation. “Other pharmaceutical companies are also weighing this option and if the biggest of the bunch decides to exit the party, it might have a ripple effect on the others,” he told Newsweek. Private foundations and government-funded research initiatives can work to keep up the pipeline of basic science, but ultimately it takes funding from a large company to get a treatment onto the shelves of CVS or Walgreens, he said.
https://www.yahoo.com/news/trump-tax-break-pfizer-ends-130002411.html